

**From:** Pamela White  
**Sent:** Wednesday, April 17, 2024 8:11 AM  
**To:** Pharmacy Services  
**Subject:** DUR Board Meeting

Good morning, I hope this email finds you well.

My name is Pamela White. I am the Founder and Executive Director of Bridging the Gap- Adult Sickle Cell Disease foundation of Nevada. I am writing to express my full support of the adoption of Casgevy and Lyfgenia, the two recent FDA approved gene therapies for Sickle Cell Disease. As a mother of two adults living with Sickle Cell Disease, and having a concern for our healthcare and the well being of others affected by this disease, I believe that these two therapies would offer a significant break through in curing this debilitating disease.

I urge the DUR Board to prioritize the adoption of both new gene therapies, Casgevy and Lyfgenia in the State of Nevada. By integrating these gene therapies into our healthcare system, we have the opportunity to offer this revolutionize approach to current patients and give hope to future generations to come. Also having a chose of these two gene therapies is pertinent to the pivotal role in reducing health disparities and promoting health equity for individual with Sickle Cell Disease. Gene therapy is different from other treatments for Sickle Cell disease because it involves a complex treatment process and is only available through transplant centers that receive specialized training. Therefore people living with this disease should be able to access available gene therapy options regardless of what state they live in which could mean access to a qualified treatment center out of state.

Thank you for considering Bridging the Gap-Adult Sickle Cell foundation's input on this matter. I strongly believe that the adoption of both Casgevy and Lyfgenia for the Sickle Cell patients would be a huge step towards improving the lives of the individuals who would qualify for either of the gene therapies, and bring hope to the Sickle Cell community.

Sincerely

Pamela White Founder/Executive  
Director 702 273-6751  
[www.btgadultsicklecell.org](http://www.btgadultsicklecell.org)